Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.45 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.40 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395001 | 1.00 | GABRR1 (0.45) | GABRR1GABRR2FFAR4CA1CA2 | |
| SCHEMBL438301 | 0.85 | GSR (0.31) | CA2 | |
| SCHEMBL438302 | 0.85 | GSR (0.31) | CA2 | |
| SCHEMBL10104051 | 0.85 | GSR (0.31) | CA2 | |
| SCHEMBL16456982 | 0.77 | ALDH1A1 (0.40) | CA2 | |
| SCHEMBL23927701 | 0.73 | GSR (0.31) | CA2 | |
| SCHEMBL23927677 | 0.73 | GSR (0.31) | CA2 | |
| SCHEMBL23927675 | 0.73 | GSR (0.31) | CA2 | |
| SCHEMBL13355318 | 0.71 | — | — | |
| SCHEMBL2684842 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274279-B1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8101658-B2 | Nitric oxide donating prostamides | NICOX S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2011-04-21 | — | — | US | disclosed |
| EP-2274279-A1 | NITRIC OXIDE DONATING PROSTAMIDES | Nicox S.A. (FR) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009136281-A1 | NITRIC OXIDE DONATING PROSTAMIDES | NICOX S.A. (FR) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092590-A1 | NITRIC OXIDE DONATING PROSTAMIDES | PTGIS, PTGIR, NOS2 | GABRR1 735/4885GABRR2 626/4885FFAR4 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.